Natco Pharma + Eris Lifesciences (Partnership) The companies have partnered to commercialize a generic semaglutide formulation targeting Type-2 diabetes management
The newest medication in this drug class came out in the summer of 2022
Its primary mechanism is the upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) two of the most important proteins governing neuronal survival, plasticity, and the formation of new neural connections
References (For Scientific Context) Benoist CC et al., , 2014 Journal of Pharmacology and Experimental Therapeutics Wright JW et al., , 2015 Journal of Alzheimers Disease Sun X et al., , 2021 Brain Sciences Reviews There are no reviews yet
Although the active ingredient is supposed to be obtained from FDA-approved manufacturing facilities, there have been reports of differences in the active ingredient and formulation components that may affect kinetics and efficacy
The formula addresses hot flushes, mood fluctuations, and hormonal imbalances that characterise this life stage